Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.

Metzelder, S K; Schroeder, T; Lübbert, M; Ditschkowski, M; Götze, K; Scholl, S; Meyer, R G; Dreger, P; Basara, N; Fey, Martin; Salih, H R; Finck, A; Pabst, Thomas; Giagounidis, A; Kobbe, G; Wollmer, E; Finke, J; Neubauer, A; Burchert, A (2017). Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. European journal of cancer, 86, pp. 233-239. Elsevier 10.1016/j.ejca.2017.09.016

[img] Text
1-s2.0-S0959804917312972-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (620kB) | Request a copy

BACKGROUND

Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available.

METHODS

We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD-positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy.

FINDINGS

With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years.

INTERPRETATION

Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Fey, Martin and Pabst, Thomas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0959-8049

Publisher:

Elsevier

Language:

English

Submitter:

Nicole Corminboeuf

Date Deposited:

21 Feb 2018 11:23

Last Modified:

29 Oct 2019 02:43

Publisher DOI:

10.1016/j.ejca.2017.09.016

PubMed ID:

29055209

Uncontrolled Keywords:

Acute myeloid leukemia FLT3-ITD Hematopoietic stem cell transplantation Sorafenib

BORIS DOI:

10.7892/boris.111188

URI:

https://boris.unibe.ch/id/eprint/111188

Actions (login required)

Edit item Edit item
Provide Feedback